Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients

Fig. 3

Cumulative virologic response (VR) rate. a Cumulative VR rates at 3, 6, 12, 24 and 36 months were 20%, 54%, 79%, 86% and 91%, respectively. b Cumulative VR rates were not significant different between the two groups (P = 0.222). c Cumulative VR rates of tenofovir group were higher than those of entecavir group, in the hepatitis B e antigen (HBeAg) positive patients. d The difference of cumulative VR rates was more evident in HBeAg-positive patients with a higher hepatitis B virus DNA levels (>6 log10 IU/mL)

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us